G60 G62 M79.2 B02.2 T14 T94
Conditions
Interventions
Group 1: A functional laser-Doppler-flowmetry will be conducted, in order to quantify functionality of vasoactive C-fibers.
Further on Quantitative Sensory Testing, a blood analysis for SNPs (single n
Sponsors
Sektion für Neurologische Schmerzforschung und Therapie, Klinik für Neurologie, UKSH Campus Kiel
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: Healthy control group: General inclusion criteria: 1. Healthy volunteers have to sign informed consent, whereby they confirm that they have been informed about the intent and purpose of the study. 2. Male or female > 18 years. 3. Study participants have to be able to describe and characterize localization and pain intensity and need to be able to complete all questionnaires within the study. 4. Eligibility of participants will be assessed by an screening test for healthy volunteers (Gierthmuhlen et al., 2015) Study specific inclusion criteria: 5. No pain disorder in the medical history. Patient group: General inclusion criteria: 1. Patients have to sign informed consent, whereby they confirm that they have been informed about the intent and purpose of the study. 2. Male or female > 18 years. 3. Study participants have to be able to describe and characterize localization and pain intensity and need to be able to complete all questionnaires within the study. 4. Patients with chronic pain disorders.
Exclusion criteria
Exclusion criteria: Healthy control group: General exclusion criteria: 1. Previous alcohol, drug or medicine abuse or reasonable suspicion. 2. Other disease altering pain perception or immunological processes. 3. Known immunodeficiency or pregnancy Patient group: General exclusion criteria: 1. Previous alcohol, drug or medicine abuse or reasonable suspicion. 2. Other disease altering pain perception or immunological processes. 3. Known immunodeficiency or pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A functional laser-Doppler-flowmetry will be conducted, in order to quantify functionality of vasoactive C-fibers. | — |
Secondary
| Measure | Time frame |
|---|---|
| Further on Quantitative Sensory Testing, a blood analysis for SNPs (single nucleotid polymorphisms) as well as a pain evaluation within several questionnaires (NRS, painDetect, NPSI, PCS, PSQ, MPSS, HADS, SF-12) will be performed. 30 days after Capsaicin application the questionnaires NRS, painDetect, NPSI and SF-12 will be reevaluated as well as fLDF in a subgroup. Additionally, a telephone interview assessing general impression of change (PGIC, CGIC) will be conducted 2, 10, and 12 weeks after treatment. | — |
Countries
Germany
Contacts
Public ContactJulia Forstenpointner
Sektion für Neurologische Schmerzforschung und Therapie, Klinik für Neurologie, UKSH Campus Kiel
Outcome results
None listed